Article Sidebar
Published:
Jun 22, 2021Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Effect of expression levels of multidrug resistance gene related protein 1, P-glycoprotein and topoisomerase II on paclitaxel, gemcitabine and vinorelbine sensitivity in pulmonary cancer
Abstract
Purpose: To investigate the possible correlation between drug resistance gene expression and development of drug sensitivity, and the possible clinical significance of this relationship.
Methods: A total of 100 cancer samples were surgically obtained. MTT assay was employed to determine drug sensitivity. The expression levels of drug resistance genes, multidrug resistance generelated protein 1 (MRP1), P-glycoprotein (P-gp), and topoisomerase II (Topo II) were measured by immunohistochemistry.
Results: The expression levels of MRP1, P-gp, and Topo II genes in lung cancer were 70.0, 65.0, and 50.0 %, respectively. No significant statistical differences were observed in the expressions of MRP1, Pgp, and Topo II between human adenocarcinoma and squamous cell carcinoma (p > 0.05), but a significant difference was found in MRP1 and Topo II expressions between human adenocarcinoma or squamous carcinoma cell and small-cell lung cancer (p < 0.05). A significant positive correlation was observed between P-gp expression and resistance cisplatin, gemcitabine, vinorelbine, and paclitaxel (p < 0.05). A significant positive correlation was also found between MRP1 expression and the development of resistance to cisplatin, gemcitabine, and vinorelbine (p < 0.05), but no significant correlation was observed between MRP1 expression and the development of resistance to paclitaxel and ifosfamide (p > 0.05).
Conclusion: The up-regulated expression of MRP1 and P-gp, and the down-regulated expression of Topo II may be positively correlated with drug resistance in lung cancer patients. Thus, gene tests are recommended to guide the administration of chemotherapy
